The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.
In sufficiently high concentrations, elemental impurities, typically from catalyst residue, can pose safety risks. The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.
Read this articlefrom Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
2016 Solid Dosage Drug Development and Manufacturing eBook.Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.